Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

TIGIT in particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months ...

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...

Pharmaceuticals are exempt from the cascade of 'Liberation Day' tariffs revealed by President Donald Trump – for now – but ...

The agreement with the GKV-Spitzenverband – the national association of statutory health insurance funds – means that Hemgenix (etranacogene dezaparvovec) can now be reimbursed across Germany's health ...

Under Kennedy's plan, the FDA is set to bear the brunt of the job losses, with 3,500 workers due to be shed, while the CDC is ...

Traditional DCTs primarily focus on prospective data collection, adapting interventional research processes to virtual approaches and providing an incomplete picture of patients. This approach offers ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

The Labour manifesto pledged to “maximise our potential to lead the world in clinical trials”. With our regulatory advantage ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...

The latest rejection looks set to mark the end of J&J's drive to resolve the litigation through the bankruptcy courts, as the ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...